Predictors of long-term HIV RNA suppression on darunavir/ritonavir monotherapy in the MONET trial. - Suppr | 超能文献

Predictors of long-term HIV RNA suppression on darunavir/ritonavir monotherapy in the MONET trial.

作者信息

Arribas Jose, Pulido Federico, Hill Andrew, Delft Yvon van, Moecklinghoff Christiane

机构信息

Hospital la Paz, IdiPAZ, Madrid, Spain.

出版信息

Int J STD AIDS. 2013 Aug;24(8):679-81. doi: 10.1177/0956462413486461.

DOI:10.1177/0956462413486461

Abstract

摘要

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1

Predictors of long-term HIV RNA suppression on darunavir/ritonavir monotherapy in the MONET trial.

Int J STD AIDS. 2013 Aug;24(8):679-81. doi: 10.1177/0956462413486461.

2

Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study.达芦那韦/利托那韦单药治疗 HIV-1 病毒抑制患者的长期疗效：来自 MONOI ANRS 136 研究的第 96 周结果。

J Antimicrob Chemother. 2012 Mar;67(3):691-5. doi: 10.1093/jac/dkr504. Epub 2011 Dec 7.

3

Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136.达芦那韦/利托那韦维持单药治疗对 HIV-1 病毒抑制患者的疗效：一项随机、开放标签、非劣效性试验，MONOI-ANRS 136。

AIDS. 2010 Sep 24;24(15):2365-74. doi: 10.1097/QAD.0b013e32833dec20.

4

Efficacy of a reduced dose of darunavir/ritonavir in a small cohort of antiretroviral-naïve HIV-infected patients.

AIDS Patient Care STDS. 2013 Jun;27(6):315-6. doi: 10.1089/apc.2013.0061. Epub 2013 May 23.

5

Darunavir/ritonavir monotherapy in clinical practice.

AIDS. 2011 Jan 2;25(1):119. doi: 10.1097/QAD.0b013e3283405d2c.

6

The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV-1 RNA copies/mL at baseline.MONET 试验：基线时病毒载量 < 50 HIV-1 RNA 拷贝/ml 的患者中，达芦那韦/利托那韦（DRV/r）单药治疗与 DRV/r 加两种核苷逆转录酶抑制剂治疗的疗效的 144 周分析。

HIV Med. 2012 Aug;13(7):398-405. doi: 10.1111/j.1468-1293.2012.00989.x. Epub 2012 Mar 14.

7

Resistant minority species are rarely observed in patients on darunavir/ritonavir monotherapy.在接受达芦那韦/利托那韦单药治疗的患者中很少观察到耐药少数物种。

J Antimicrob Chemother. 2012 Jun;67(6):1470-4. doi: 10.1093/jac/dks052. Epub 2012 Mar 5.

8

Use of darunavir/ritonavir once daily in treatment-naive pregnant woman: pharmacokinetics, compartmental exposure, efficacy and safety.初治孕妇每日一次使用达芦那韦/利托那韦：药代动力学、房室暴露、疗效及安全性

AIDS. 2010 Apr 24;24(7):1083-4. doi: 10.1097/QAD.0b013e32833653b2.

9

Analysis of drug resistance during HIV RNA viraemia in the MONET trial of darunavir/ritonavir monotherapy.在达芦那韦/利托那韦单药治疗的MONET试验中对HIV RNA病毒血症期间的耐药性分析。

Antivir Ther. 2011;16(1):59-65. doi: 10.3851/IMP1710.

10

Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients.第 48 周分析每日一次与每日两次使用达芦那韦/利托那韦治疗经治 HIV-1 感染患者的疗效。

AIDS. 2011 Apr 24;25(7):929-39. doi: 10.1097/QAD.0b013e328345ee95.

引用本文的文献

1

HIV Viral Dynamics of Lopinavir/Ritonavir Monotherapy as Second-Line Treatment: A Prospective, Single-Arm Trial.洛匹那韦/利托那韦单药治疗作为二线治疗的HIV病毒动力学：一项前瞻性单臂试验。

J Int Assoc Provid AIDS Care. 2019 Jan-Dec;18:2325958218823209. doi: 10.1177/2325958218823209.

2

Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients.优化在病毒学抑制的HIV感染患者中选择安全的洛匹那韦/利托那韦或达芦那韦/利托那韦单药治疗候选者的标准。

PLoS One. 2017 Feb 13;12(2):e0171611. doi: 10.1371/journal.pone.0171611. eCollection 2017.